Generic Peptide Name,Application,Indication,sequence,SMILE code,SMILES A/B,Unnamed: 7,Molar Mass (g/mol),Constitutional members,Natural amino acids,D-Aas,cycle,Members/Macrocycle,Bond to form cycle,Lipidation,Glycosylation,half_life_seconds,Protein Binding,Bioavailability,Route of Administration,Country ,Agency,Year ,Design,Origin,Production Method,1,2,3,4,5,6,7,8,9,10,modifications,is_mod
Oxytocin,Therapeutic,"Used for labor induction, augmentation of labor, postpartum abbreviation of third stage of labor, postpartum control of uterine bleeding, termination of pregnancy and for the evaluation of fetal respiratory capability",CYIQNCPLG-NH2,CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N,A,A,1007.19,9,9,0,yes,6,side chain-to-side chain (disulfide),no,no,1-6min,No protein binding to plasma proteins.,"Bioavailability is poor, subject-dependent and ranges between 0.007 and 0.07% (CV = 50.0 %) with the assumption that the total body clearance is similar after intravenous and sublingual administration.","IV, IM",US,FDA,1980,Natural,Oxytocin,Synthesis - Solid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB00107,https://onlinelibrary.wiley.com/doi/abs/10.1111/j.2042-7158.1995.tb06716.x,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018261s031lbl.pdf,https://www.dgidb.org/drugs/OXYTOCIN#_summary,https://www.sciencedirect.com/science/article/pii/B9780080552323623542 ,,,,,,"H, NH2",True
Vasopressin (or Argipressin),Therapeutic,"For the treatment of enuresis, polyuria, diabetes insipidus, polydipsia and oesophageal varices with bleeding,in abdominal roentgenography to dispel interfering gas shadows, and for the prevention and treatment of postoperative abdominal distention.",CYFQNCPRG-NH2,C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N,A,A,1084.24,9,9,0,yes,6,side chain-to-side chain (disulfide),no,no,10-20 min,1%,Vasopressin has almost 0% oral bioavailability,"IM, SC, IV, NASAL",US,FDA,-,Natural,Vasopressin,Synthesis - Recombinant,https://go.drugbank.com/drugs/DB00107,https://derangedphysiology.com/main/cicm-primary-exam/required-reading/cardiovascular-system/Chapter%20722/vasopressin,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204485Orig1s000lbl.pdf,,,,,,,,"H, NH2",True
Leuprolide,Therapeutic,"Palliative treatment of advanced prostate cancer and treatment of pediatric patients with central precocious puberty (CPP), initial treatment of the symptoms of endometriosis.",XHWSYlLRP-NHEt,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1,A,B,1209.421,9,7,1,no,N.A.,N.A.,no,no,Leuprolide has a terminal elimination half-life of approximately 3 hours,43-49%,Bioavailability by subcutaneous administration is comparable to that of intravenous administration,"SC, IM, TOPICAL",US,FDA,1985,Analogue,Gonadotropin-releasing hormone (GnRH),Synthesis - Solid Phase and Liquid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB00007,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020517s036_019732s041lbl.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203696Orig1s000SumR.pdf,"https://cpcscientific.com/leuprolide/#:~:text=The%20process%20begins%20with%20the,of%20H%2DPro%2DNHEt.",,,,,,,"pyroglutamyl, NHEt",True
Abarelix,Therapeutic,For palliative treatment of advanced prostate cancer.,Ac-XXXSXnLXPa-NH2,CC(C)C[C@H](NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=C(C=CC=C2)C=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,A,B,1416.09,10,3,5,no,N.A.,N.A.,no,no,0.22 days (5.3 h) for abarelix injectable solution and 13.2 days for abarelix depot injection,96-99%,The mean relative bioavailability of the depot formulation in reference to the injectable solution was 0.52.,IM,US,FDA,2003,Analogue,Gonadotropin-releasing hormone (GnRH),Synthesis - Solid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB00106,https://pubmed.ncbi.nlm.nih.gov/15102870/,https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21320_plenaxis_lbl.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-320_Plenaxis.cfm,https://patents.google.com/patent/CN107778354B/en,,,,,,"acetyl, NH2",True
Daptomycin,Therapeutic,Lipopeptide antibiotic active against Gram-positive bacteria only.,Dec-WnDTGXDaDGsXX,CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=CC=CC=C2N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O,A,B,1620.693,14,7,3,yes,10,head-to-side chain (Kyn-Tyr),yes,no,8-9 hours (up to 28 hours in renal impairment),90-93%,Generally exhibits linear and time-independent pharmacokinetics at a dosage of 4–12 mg/kg IV once every 24 hours. Steady-state trough serum concentrations are achieved by the third daily dose.,IV,US,FDA,2003,Natural,Soil bacterium Streptomyces roseosporus,Fermentation - Isolated from Streptomyces roseosporus,https://go.drugbank.com/drugs/DB00080,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf,https://www.fda.gov/media/123630/download,,,,,,,,"decanoyl, cycle",True
Teicoplanin,Therapeutic,For the treatment of bacterial infections caused by susceptible microorganisms.,-,CCCCCCCCCC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)[C@H]([C@H]6C(=O)N[C@@H](C7=C(C(=CC(=C7)O)OC8[C@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C9=C(C=CC(=C9)[C@H](C(=O)N6)NC(=O)[C@@H]4NC(=O)[C@@H]1C2=CC(=CC(=C2)OC2=C(C=CC(=C2)[C@H](C(=O)N[C@H](CC2=CC(=C(O3)C=C2)Cl)C(=O)N1)N)O)O)O)C(=O)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)NC(=O)C)Cl)CO)O)O,B,B,1879.67,N.A.,N.A.,N.A.,yes,multicyclic,C-O-C; C-C,yes,yes - 3 sugars,70-100 hours,90-95%,90%,"IM, ORAL",Italy,AIFA,1987,Natural,Fermentation broth of a strain of Actinoplanes teichomyceticus,Fermentation - Extracted from Actinoplanes teichomyceticus,https://go.drugbank.com/drugs/DB06149,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/060180s047lbl.pdf,https://link.springer.com/article/10.1007%2Fs40261-017-0524-1,https://www.ema.europa.eu/en/documents/referral/assessment-report-article-53-procedure-teicoplanin-containing-medicinal-products_en.pdf,,,,,,,"H, OH",True
Gramicidin D,Therapeutic,"For treatment of skin lesions, surface wounds and eye infections.",Formyl-VGAlAvVVWlWlWlWX,C[C@@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC7=CNC8=CC=CC=C87)C(=O)NCCO)NC(=O)CNC(=O)[C@H](C(C)C)NC=O,A,B,1882.332,16,10,5,no,N.A.,N.A.,no,no,-,-,-,"TOPICAL, AURICOLAR, OPHTALMIC, NASAL",US,FDA,1955,Natural,Soil bacterial species Bacillus brevis,Fermentation - Isolated from Bacillus brevis,https://go.drugbank.com/drugs/DB00027,https://www.mdpi.com/2079-6382/9/1/24/htm,,,,,,,,,"formyl, OH",True
Bivalirudin,Therapeutic,"For treatment of heparin-induced thrombocytopenia and for the prevention of thrombosis. Bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention (PCI), in patients at moderate to high risk acute coronary syndromes due to unstable angina or non-ST segment elevation in whom a PCI is planned.",fPRPGGGGNGDFEEIPEEYL,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O,A,B,2180.317,20,19,1,no,N.A.,N.A.,no,no,25 min (up to 3.5h for dyalisis-dependant patients),"Other than thrombin and red blood cells, bivalirudin does not bind to plasma proteins.",The bioavailability of bivalirudin for intravenous use is complete and immediate.,"IV, IC",US,FDA,2000,Analogue,Hirudin,Synthesis - Solid Phase and Liquid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB00006,https://www.medicines.org.uk/emc/product/7229/smpc#gref,https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20873lbl.pdf,https://www.ema.europa.eu/en/documents/scientific-discussion/angiox-epar-scientific-discussion_en.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208374s000lbl.pdf,,,,,,"H, OH",True
Sinapultide,Therapeutic,Prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.,KLLLLKLLLLKLLLLKLLLLK,CC(C)C[C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)O)NC(=O)[C@@H](CCCCN)N,A,B,2469.45,21,0,0,no,N.A.,N.A.,no,no,-,-,-,IT,US,FDA,2012,Heterologous,Human surfactant protein B (SP-B),Synthesis - Liquid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB11332,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021746s000lbl.pdf,https://drugs.ncats.io/drug/040X3AX99T,https://patents.google.com/patent/WO2020062782A1/en,,,,,,,"H, OH",True
Tetracosactide,Diagnostic,For use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.,SYSMEHFRWGKPVGKKRRPVKVYP,CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(O)=O,A,B,2933.49,24,24,0,no,N.A.,N.A.,no,no,15 min (IV),-,Rapidly absorbed following intramuscular administration.,"IM, IV, PARENTERAL",UK,MHRA,1965,Analogue,Adrenocorticotropic hormone (ACTH),Synthesis - Solid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB01284,https://www.medicines.org.uk/emc/product/10822/smpc#gref,https://apps.medicines.org.au/files/iypsynad.pdf,https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/a-pkpd-of-synacthen-formulations-administered-by-different-routes/,https://patents.google.com/patent/CN103159850A/en,,,,,,"H, OH",True
Salmon Calcitonin,Therapeutic,Treatment of symptomatic Paget's disease for patients unresponsive to alternate treatments or intolerant to such treatments; emergency situations when serum calcium levels must be decreased quickly until the underlying condition is identified; added to existing therapeutic regimens for hypocalcemia; in patients with azotemia; for treatment of post-menopausal osteoporosis.,CSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP-NH2,CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@H]([C@@H](C)O)C(=O)N1)C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@@H]([C@H](C)O)C(=O)N[C@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]([C@@H](C)O)C(=O)NCC(=O)N[C@H](CO)C(=O)NCC(=O)N[C@H]([C@H](C)O)C(=O)N1CCC[C@@H]1C(N)=O,A,B,3431.9,32,32,0,yes,7,side chain-to-side chain (disulfide),no,no,"59-64min (SC), 58min (IM), 18-23min (NS)",30-40%,"71% (SC), 66% (IM), 3-5% (NASAL)","NASAL Spray, IM, SC",US,FDA,1978,Natural,Salmon Calcitonin,Synthesis  - Solid Phase Peptide Syntheis or Recombinant DNA technology,https://go.drugbank.com/drugs/DB00017,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/017808s034lbl.pdf,https://www.ema.europa.eu/en/documents/product-information/forcaltonin-epar-product-information_en.pdf,https://www.federalregister.gov/documents/2019/09/09/2019-19347/determination-that-calcimar-calcitonin-salmon-injection-200-international-units-per-milliliter-was,https://patents.google.com/patent/US5527881?oq=US5527881,,,,,,"H, NH2",True
Teduglutide,Therapeutic,"Treatment of short bowel syndrome (SBS), malabsorption associated with the removal of the intestine, in adults patients who are dependent on parenteral support.",HGDGSFSDEMNTILDNLAARDFINWLIQTKITD,CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC5=CN=CN5)N,A,B,3752.13,33,33,0,no,N.A.,N.A.,no,no,2 hours (healthy subjects); 1.3 hours (SBS patients),-,88% (SC),SC,US,FDA,2012,Analogue,Glucagon-like peptide-1 (GLP-1),Recombinant DNA technology,https://go.drugbank.com/drugs/DB08900,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203441Orig1s002.pdf,https://www.ema.europa.eu/en/documents/assessment-report/revestive-epar-public-assessment-report_en.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203441Orig1s000lbl.pdf,,,,,,,"H, OH",True
Glucagon,"Diagnostic, Therapeutic",Indicated as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia,HSQGTFTSDYSKYLDSRRAQDFVQWLMNT,CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O,A,B,3482.8,29,29,0,no,N.A.,N.A.,no,no,"26 min (IM), 35 min (NP), 32 min (SC)",No binding,A 1mg intravenous dose of glucagon reaches a Cmax of 7.9ng/mL with a Tmax of 20 minutes.6 An intramuscular dose reaches a Cmax of 6.9ng/mL with a Tmax of 13 minutes.6 A 3mg dose of glucagon nasal powder reaches a Cmax of 6130pg/mL with a Tmax of 15 minutes.8,"NASAL, IV, IM, SC",US,FDA,1960,Natural,Glucagon,Recombinant DNA technology,https://go.drugbank.com/drugs/DB00040,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020918_S003_GLUCAGEN.pdf,,,,,,,,,"H, OH",True
Teriparatide,Therapeutic,Treatment of osteoporosis,SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF,CCC(C)C(C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)NC(CC1=CNC=N1)C(=O)NC(CC(=O)N)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC2=CNC=N2)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CCSC)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)C)C(=O)NC(CC5=CNC=N5)C(=O)NC(CC(=O)N)C(=O)NC(CC6=CC=CC=C6)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CO)N,A,B,4117.77,34,34,0,no,N.A.,N.A.,no,no,The half-life of teriparatide in serum is 5 minutes when administered by intravenous injection and approximately 1 hour when administered by subcutaneous injection.,-,95%,SC,US,FDA,2002,Analogue,Parathyroid hormone (PTH),Recombinant DNA technology,https://go.drugbank.com/drugs/DB06285,https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021318s015lbl.pdf,https://www.ema.europa.eu/en/documents/scientific-discussion/forsteo-epar-scientific-discussion_en.pdf,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-318_Forteo.cfm,,,,,,"H, OH",True
Enfuvirtide,Therapeutic,Antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS.,Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF,CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CC7=CC=CC=C7)C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CN=CN8)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC9=CC=C(C=C9)O)NC(=O)C,A,B,4491.945,36,36,0,no,N.A.,N.A.,no,no,3.8 ± 0.6 hours,92%,84.3%,SC,US-EU,FDA-EMA,2003,Analogue,Second heptad repeat (HR2) domain of the HIV-1 transmembrane glycoprotein gp41,Synthesis - Solid Phase and Liquid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB00109,https://pubmed.ncbi.nlm.nih.gov/15656696/,https://www.ema.europa.eu/en/documents/scientific-discussion/fuzeon-epar-scientific-discussion_en.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021481s032lbl.pdf,https://www.ema.europa.eu/en/medicines/human/EPAR/fuzeon,https://www.nature.com/articles/nrd1133 ,,,,,"acetyl, OH",True
Corticotropin,Diagnostic,For use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.,SYSMEHFRWGKPVGKKRRPVKVYPNGAEDESAEAFPLEF,C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]6CCCN6C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]7CCCN7C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC8=CNC9=CC=CC=C98)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CO)N,B,B,4541.14,39,39,0,no,N.A.,N.A.,no,no,15 Min (IV),-,-,"IM, SC, IV",US,FDA,1952,Natural,Adrenocorticotropic hormone (ACTH),Extracted from anterior pituitary powder,https://go.drugbank.com/drugs/DB01285,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022432s000lbl.pdf,https://www.jbc.org/article/S0021-9258(18)56218-9/pdf,,,,,,,,"H, OH",True
Tesamorelin,Therapeutic,Indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.,XYADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH2,CC\C=C\CC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(N)=O,A,B,5005.76,45,44,0,no,N.A.,N.A.,yes,no,"26 min (healthy subject), 38 min (HIV-infected patients)",-,>4% (SC),SC,US,FDA,2010,Analogue,Gonadotropin-releasing hormone (GnRH),Synthesis - Solid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB08869,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022505s012s013lbl.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022505s000lbl.pdf,https://patents.google.com/patent/CN102702343A/en ,,,,,,,"3-hexenoyl, NH2",True
Buserelin,Therapeutic,"Used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction.",XHWSYXLRP-NHEt,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6,A,B,1239.447,9,7,1,no,N.A.,N.A.,no,no,"50-80 min (IV), 80 min (SC), 1-2hour (NS)",15%,"Buserelin is water soluble and readily absorbed after subcutaneous injection (70% bioavailable). However, bioavailability after oral absorption. When administered correctly via the nasal route, it may be absorbed in the nasal mucosa to achieve sufficient plasma levels.","NASAL, SC",New Zealand,MedSafe,1990,Analogue,Luteinizing hormone-releasing hormone (LHRH),Synthesis - Solid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB06719,https://products.sanofi.ca/en/suprefact-depot.pdf,https://www.medsafe.govt.nz/profs/Datasheet/s/Suprefactinj.pdf,https://patents.google.com/patent/WO2014047822A1/en,,,,,,,"pyroglutamyl, NHEt",True
Felypressin (or Octapressin),Therapeutic,"Non-catecholamine vasoconstrictor used in local anaesthetic injections for dental use, and is an ingredient of preparations that have been used for treatment of pain and inflammation of the mouth.",CFFQNCPKG-NH2,NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,A,A,1040.23,9,9,0,yes,6,side chain-to-side chain (disulfide),no,no,-,-,-,Dental Injection,New Zealand,MedSafe,1969,Analogue,Vasopressin,Synthesis - Solid Phase Peptide Synthesis and Post Synthesis Cyclisation,https://go.drugbank.com/drugs/DB00093,https://www.medsafe.govt.nz/profs/datasheet/c/citanestwithoctapressininj.pdf,https://patents.google.com/patent/US20060276626A1/en?q=(felypressin)&oq=felypressin ,,,,,,,,"H, NH2",True
Ornipressin (or Por-8),Therapeutic,"Reduction of bleeding during surgery, variceal haemorrhage",CYFQNCPXG-NH2,NCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,A,A,1042.2,9,8,0,yes,6,side chain-to-side chain (disulfide),no,no,-,-,-,Topical or by infiltration,"Germany, Switzerland, New Zealand, Australia","Germany, Switzerland, New Zealand, Australia",1971,Analogue,Vasopressin,Synthesis - Solid Phase Peptide Synthesis and Post Synthesis Cyclisation,https://go.drugbank.com/drugs/DB13464,https://journals.lww.com/ejanaesthesiology/fulltext/1998/03000/the_pharmacology_of_ornipressin__por_8___a_local.2.aspx,https://drugs.ncats.io/substance/1KTH6N080W,https://pubchem.ncbi.nlm.nih.gov/compound/Ornipressin,https://patents.google.com/patent/US20060276626A1/en?q=(felypressin)&oq=felypressin,,,,,,"H, NH2",True
Desmopressin,Therapeutic,Treatment of nocturia due to nocturnal polyuria (intranasal); indicated as antidiuretic replacement therapy in central cranial diabetes insipidus; indicated for patients with hemopilia A.,XYFQNCPrG-NH2,NC(=O)CC[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O,A,A,1069.22,9,7,1,yes,6,side chain-to-side chain (disulfide),no,no,"Following an intranasal dose of 1.66 mcg of desmopressin, the median apparent terminal half-life was 2.8 hours. Terminal half-life significantly increased from 3 hours in normal healthy patients to 9 hours in patients with severe renal impairment. The oral terminal half life of desmopressin ranges from 2 to 3.11 hours.",17.3 ± 1.5%,The bioavailability of 1.5 mg/mL desmopressin administered by the intranasal route was between 3.3 and 4.1%. The absolute bioavailability of orally administered desmopressin varies between 0.08% and 0.16% where the mean maximum plasma concentration is reached within 2 hours.,"NASAL, ORAL, SL, IV, IM, SC",US,FDA,1978,Analogue,Vasopressin,Synthesis - Solid Phase Peptide Synthesis and Post Synthesis Cyclisation,https://go.drugbank.com/drugs/DB00035,https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21333slr001_Minirin_lbl.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018938s035lbl.pdf,https://patents.google.com/patent/US20060276626A1/en?q=(felypressin)&oq=felypressin ,,,,,,,"deamino, NH2",True
Elcatonin,Therapeutic,Molecule with calcium-regulating hormone-like actions that modulate OSTEOLYSIS and other extra-skeletal activities to maintain calcium homeostasis. It is used as an anti-parathyroid agent.,SNLSTXVLGKLSQELHKLQTYPRTDVGAGTP-NH2,CC(C)CC1C(=O)NC(C(=O)NC(C(=O)NC(CCCCCC(=O)OCC(C(=O)NC(C(=O)N1)CC(=O)N)N)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC2=CN=CN2)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(C(C)O)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)N4CCCC4C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)O)C(=O)NC(CC(=O)O)C(=O)NC(C(C)C)C(=O)NCC(=O)NC(C)C(=O)NCC(=O)NC(C(C)O)C(=O)N5CCCC5C(=O)N)C(C)O)CO,A,A,3363.827,31,30,0,yes,6,side chain-to-tail (esther Asu-Ser),no,no,Elcatonin has a short absorption and elimination half-lives of approx 4 hours,30-40%,70%,"IV, IM, NASAL",JP,PMDA,1981,Analogue,Eel Calcitonin,-,https://go.drugbank.com/drugs/DB13742,https://www.ema.europa.eu/en/documents/referral/calcitonins-article-31-referral-annex-iii_en.pdf,https://books.google.it/books?id=pyOsDwAAQBAJ&pg=PA152&lpg=PA152&dq=elcatonin+approval+year+1981&source=bl&ots=yglVlUspJe&sig=ACfU3U2YboJuwXUarnUrpKaQ7ynN_HwJ3g&hl=en&sa=X&ved=2ahUKEwjk2KCBxt_uAhUKZcAKHWkrBUwQ6AEwBnoECAkQAg#v=onepage&q=elcatonin%20approval%20year%201981&f=false,https://www.thepharmaletter.com/article/elcatonin-generics-banned-in-japan,,,,,,,"H, NH2",True
Enalapril,Therapeutic,Indicated for the management of essential or renovascular hypertension,XAP,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O,A,B,376.453,3,2,0,no,N.A.,N.A.,no,no,35-38 hours,>50%,40% (when IV as reference standard),ORAL,US,FDA,1985,Heterologous,Captopril (derived from viper's venom),-,https://go.drugbank.com/drugs/DB00584,https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018998_Vasotec.cfm,,,,,,,,,"ethyl-4-phenylbutanoyl, OH",True
Triptorelin,Therapeutic,indicated for the palliative treatment of advanced prostate cancer.,XHWSYwLRPG-NH2,CC(C)C[C@H](NC(=O)[C@@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,B,B,1311.473,10,8,1,no,N.A.,N.A.,no,no,"3 Compartment model: 6 min, 45 min, and 3 hours respectively.",No binding,100% (IV),"SC, IM",US,FDA,2000,Analogue,Luteinizing hormone-releasing hormone (LHRH),Synthesis - Solid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB06825,https://pubchem.ncbi.nlm.nih.gov/compound/Triptorelin-pamoate,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020715s040,021288s035,022427s015lbl.pdf",https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-715_Trelstar.cfm,https://patents.google.com/patent/CN101357936B/en ,,,,,,"pyroglutamyl, NH2",True
Human Calcitonin,Therapeutic,Human calcitonin is indicated for the treatment of Paget's disease in the cases where the use of salmon calcitonin may provoke the generation of high-titer of antibodies,CGNLSTCMLGTYTQDFNKFHTFPQTAIGVGAP-NH2,CCC(C)C(C(=O)NCC(=O)NC(C(C)C)C(=O)NCC(=O)NC(C)C(=O)N1CCCC1C(=O)N)NC(=O)C(C)NC(=O)C(C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C2CCCN2C(=O)C(CC3=CC=CC=C3)NC(=O)C(C(C)O)NC(=O)C(CC4=CNC=N4)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(CCCCN)NC(=O)C(CC(=O)N)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)O)NC(=O)C(CC7=CC=C(C=C7)O)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CC(C)C)NC(=O)C(CCSC)NC(=O)C8CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N8)C(C)O)CO)CC(C)C)CC(=O)N)N,A,B,3417.88,32,32,0,yes,7,side chain-to-side chain (disulfide),no,no,10.2-37.8 min,30-40%,0.01-2.7%,"IM, SC",-,-,1986,Natural,Human Calcitonin,Synthesis - Solid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB06773,https://www.ema.europa.eu/en/documents/referral/calcitonins-article-31-referral-annex-iii_en.pdf,https://books.google.it/books?id=pyOsDwAAQBAJ&pg=PA152&lpg=PA152&dq=elcatonin+approval+year+1981&source=bl&ots=yglVlUspJe&sig=ACfU3U2YboJuwXUarnUrpKaQ7ynN_HwJ3g&hl=en&sa=X&ved=2ahUKEwjk2KCBxt_uAhUKZcAKHWkrBUwQ6AEwBnoECAkQAg#v=onepage&q=elcatonin%20approval%20year%201981&f=false,"https://www.sciencedirect.com/science/article/pii/S0960894X0200344X#:~:text=In%20the%20early%20synthesis%20of,oxidize%20the%20methionine%20side%20chain. ",,,,,,,"H, NH2",True
Goserelin,Therapeutic,Indicated for palliative treatment of advanced prostate carcinoma; palliative treatment of advanced breast cancer; management of endometriosis; endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding; used in combination with flutamide for locally confined postate carcinoma.,XHWSYXLRP-NHNHCONH2,CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,A,B,1269.433,10,7,1,no,N.A.,N.A.,no,no,4-5 hours,27.3%,"Inactive orally, rapidly absorbed following subcutaneous administration.",SC,US,FDA,1989,Analogue,Gonadotropin-releasing hormone (GnRH),Synthesis - Solid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB00014,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020578s034,020578s035lbl.pdf","https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019726s059,020578s037lbl.pdf",https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019726s050s051s052lbl.pdf,https://patents.google.com/patent/CN102746383A/en ,,,,,,"H, NHNHCONH2",True
Octreotide,Therapeutic,For treatment of acromegaly and reduction of side effects from cancer chemotherapy,fCFwKTCX,[H][C@]1(NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@H](CO)[C@@H](C)O)NC(=O)[C@H](N)CC1=CC=CC=C1)[C@@H](C)O,A,A,1019.25,8,5,2,yes,6,side chain-to-side chain (disulfide),no,no,100 min (SC),65%,100% (SC),"SC, IV, IM",US,FDA,1988,Analogue,Somatostatin,Synthesis - Hybrid Solid Phase-Liquid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB00104,https://pubmed.ncbi.nlm.nih.gov/8287633/,https://gut.bmj.com/content/gutjnl/35/3_Suppl/S1.full.pdf,https://www.ema.europa.eu/en/documents/variation-report/afinitor-h-c-1038-ii-0008-epar-assessment-report-variation_en.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021008s043lbl.pdf,"https://patents.google.com/patent/WO2005087794A1/en#:~:text=1.-,A%20process%20for%20obtaining%20octreotide%20or%20a%20pharmaceutically%20acceptable%20salt,or%20more%20amino%20acid%20residues%2C ",,,,,"H, OH",True
Gonadorelin,Diagnostic,For evaluating the functional capacity and response of the gonadotropes of the anterior pituitary also for evaluating residual gonadotropic function of the pituitary following removal of a pituitary tumor by surgery and/or irradiation.,XHWSYGLRPG-NH2,CC(C)CC(NC(=O)CNC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CO)NC(=O)C(CC1=CNC2=CC=CC=C12)NC(=O)C(CC1=CN=CN1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O,A,B,1182.311,10,9,0,no,N.A.,N.A.,no,no,10-40min,-,The absolute bioavailability of gonadorelin (IM versus IV) was estimated to be around 89%.,"IV, SC",Canada,CADTH,1976,Analogue,Gonadotropin-releasing hormone (GnRH),Synthesis - Solid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB00644,https://patents.google.com/patent/CN106432427A/en ,,,,,,,,,"pyroglutamyl, NH2",True
Histrelin,Therapeutic,"As the product Supprelin LA (FDA), histrelin is indicated for the treatment of children with central precocious puberty (CPP). As the product Vantas (FDA), histrelin is indicated for the palliative treatment of advanced prostate cancer.",XHWSYXLRP-NHEt,CC(O)=O.CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC1=CN(CC2=CC=CC=C2)C=N1)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1,B,B,1443.632,9,7,1,no,N.A.,N.A.,no,no,3.92 ± 1.01 hr,"For the product Vantas, the fraction of drug unbound in plasma measured in vitro was 29.5% Â± 8.9% (mean Â± SD).",92%,SC,US,FDA,2004,Analogue,Gonadotropin-releasing hormone (GnRH),Synthesis - Hybrid Solid Phase-Liquid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB06788,https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021732s013lbl.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021732s000_VantasTOC.cfm,https://patents.google.com/patent/CN102850437A/en ,https://patents.google.com/patent/CN102850437A/en ,,,,,,"pyroglutamyl, NHEt",True
Lanreotide,Therapeutic,treatment of neuroendocrine tumours and acromegaly.,XCYwKVCT-NH2,[H]N([H])CCCCC1N([H])C(=O)C(CC2=CN([H])C3=CC=CC=C23)N([H])C(=O)C(CC2=CC=C(O)C=C2)N([H])C(=O)C(CSSCC(N([H])C(=O)C(N([H])C1=O)C(C)C)C(=O)N([H])C(C(C)O)C(=O)N([H])[H])N([H])C(=O)C(CC1=CC2=CC=CC=C2C=C1)N([H])[H],A,A,1096.33,8,6,2,yes,6,side chain-to-side chain (disulfide),no,no,22 days,-,"Lanreotide forms a drug depot at the site of injection; therefore, there are 2 phases that describe the absorption of Lanreotide: 1. Initial rapid subcutaneous release during the first few days of treatment where drug that has not precipitated is rapidly absorbed. 2. Slow release of drug from the depot via passive diffusion. Absorption is independent of body weight, gender, and dosage.",SC,US,FDA,2007,Analogue,Somatostatin,Synthesis - Liquid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB06791,https://ipsen.com/websites/IPSENCOM-PROD/wp-content/uploads/sites/18/2019/05/22160458/0069-ca-m131-somatuline-autogel-pm-clean.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022074s010lbl.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022074s022lbl.pdf,"https://patents.google.com/patent/WO2017178950A1/en#:~:text=Lanreotide%20acetate%20was%20first%20disclosed,coupled%20successively%20with%20Boc%2DS%2D ",,,,,,"H, NH2",True
Degarelix,Therapeutic,Treatment of advanced prostate cancer,Ac-XXXSXXfXLXPa-NH2,CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=C(NC(N)=O)C=C1)NC(=O)[C@H](CC1=CC=C(NC(=O)[C@@H]2CC(=O)NC(=O)N2)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,A,B,1632.29,12,3,5,no,N.A.,N.A.,no,no,41.5 - 70.2 days,90%,30-40%,SC,US,FDA,2008,Analogue,Gonadotropin-releasing hormone (GnRH),Synthesis - Solid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB06699,https://www.standardofcare.com/showarticle.php?artid=2538,https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022201lbl.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022201s016lbl.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022201s000_TOC.cfm,https://patents.google.com/patent/WO2011066386A1/en,,,,,"acetyl, NH2",True
Icatibant,Therapeutic,Approved for treatment of hereditary angioedema in EU; orphan drug in USA,rRPXGXSXR,[H][C@]12C[C@]([H])(N(C(=O)[C@@]3([H])CC4=C(CN3C(=O)[C@H](CO)NC(=O)[C@H](CC3=CC=CS3)NC(=O)CNC(=O)[C@]3([H])C[C@@H](O)CN3C(=O)[C@@H]3CCCN3C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](N)CCCNC(N)=N)C=CC=C4)[C@@]1([H])CCCC2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O,B,B,1304.54,10,5,2,no,N.A.,N.A.,no,no,1-2 hours,-,97%,SC,EU,EMA,2008,Analogue,Bradikynin,Synthesis - Solid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB06196,https://www.ema.europa.eu/en/documents/product-information/firazyr-epar-product-information_en.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022150s000lbl.pdf,https://www.ema.europa.eu/en/medicines/human/EPAR/firazyr,https://patents.google.com/patent/WO2019064220A1/en ,,,,,,"H, OH",True
Linaclotide,Therapeutic,Treatment of irritable bowel syndrome (IBS) with constipation and chronic idiopathic constipation.,C(1)C(2)EYC(3)C(1)NPAC(2)TGC(3)Y,[H][C@]1(CSSC[C@]2([H])NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]3CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CSSC[C@H](N)C(=O)N3)NC2=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)NCC(=O)N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O,A,B,1526.73,14,14,0,yes,multicyclic,3 side chain-to-side chain (disulfide),no,no,Can't be calculated because not sistemically absorbed,-,"When taken orally, linaclotide is not absorbed into the systemic",ORAL,US-EU,FDA-EMA,2012,Analogue,"E.Coli enterotoxin, Guanylin, Uroguanylin",Synthesis - Solid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB08890,https://www.ema.europa.eu/en/documents/assessment-report/constella-epar-public-assessment-report_en.pdf,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3638410/,https://www.sciencedirect.com/science/article/pii/S1001841718300056 ,,,,,,,"H, OH",True
Carfilzomib,Therapeutic,Indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. ,XXLFX,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,A,B,719.924,5,2,0,no,N.A.,N.A.,no,no,≤1 hour,97%,-,IV,US,FDA,2012,Analogue,Epoxomicin,Synthesis - Liquid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB08889,https://www.ema.europa.eu/en/documents/assessment-report/kyprolis-epar-public-assessment-report_en.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202714s025lbl.pdf,https://patents.google.com/patent/WO2016069479A1/en ,,,,,,,"2-morpholinacetyl, 2-amino-4-methyl-1-[2-methyloxiran-2-yl]pentan-1-one ",True
Etelcalcetide,Therapeutic,indicated for: Secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.,Ac-c(C)-arrrar-NH2,C[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@H](N)C(O)=O)NC(C)=O)C(=O)N[C@H](CCCNC(N)=N)C(N)=O,A,B,1048.26,8,1,7,no,N.A.,N.A.,no,no,3-4 days,Etelcalcetide is predominately bound to plasma albumin by reversible covalent binding. Non-covalent binding of etelcalcetide to plasma proteins is low with a fraction unbound ratio of 0.53. The ratio of blood-to-plasma [14C]-etelcalcetide concentrations is approximately 0.6.,-,IV,EU,EMA,2016,Heterologous,Calcimimetic,Synthesis - Liquid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB12865,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208325Orig1s000SumR.pdf,https://www.ema.europa.eu/en/documents/product-information/parsabiv-epar-product-information_en.pdf,https://www.ema.europa.eu/en/medicines/human/EPAR/parsabiv,https://patents.google.com/patent/WO2017114240A1/en ,,,,,,"acetyl, NH2",True
Abaloparatide,Therapeutic,Approved in 2017 by the FDA (as Tymlos) for the treatment of postmenopausal women with osteoporosis at high risk for fracture.,AVSEHQLLHDKGKSIQDLRRRELLEKLLXKLHTA-NH2,CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NC(C)(C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)N,A,B,3960.657,34,33,0,no,N.A.,N.A.,no,no,1.7 (0.7) hrs,70%,36%,SC,US,FDA,2017,Analogue,Parathyroid hormone-related protein (PTHrP),Synthesis - Solid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB05084,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208743Orig1s000SumR.pdf,https://www.ema.europa.eu/en/documents/assessment-report/eladynos-epar-refusal-public-assessment-report_en.pdf,https://patents.google.com/patent/WO2020208650A1/en ,,,,,,,"H, NH2",True
Plecanatide,Therapeutic,Treatment of chronic idiopathic constipation (CIC),NDEC(1)ELC(2)VNVAC(1)TGC(2)L,[H][C@@]12CSSC[C@H](NC(=O)CNC(=O)[C@@]([H])(NC(=O)[C@]([H])(CSSC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC2=O)C(C)C)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O,A,B,1681.89,16,16,0,yes,multicyclic,2 side chain-to-side chain (disulfide),no,no,Half-life (t½) cannot be calculated due to negligible systemic absorbance,Plecanatide exhibits little to no binding to human serum albumin or human α-1-acid glycoprotein.,"Plecanatide is minimally absorbed with negligible systemic availability following oral administration. Concentrations of plecanatide and its active metabolite in plasma are below the limit of quantitation after an oral dose of 3 mg. Therefore, standard pharmacokinetic parameters such as AUC, maximum concentration (Cmax), and half-life (t½) cannot be calculated.",ORAL,US,FDA,2017,Analogue,Uroguanylin,Synthesis - Solid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB13170,https://drugs.ncats.io/substance/7IK8Z952OK,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208745Orig1s000CrossR.pdf,https://patents.google.com/patent/CN104628827A/en ,,,,,,,"H, OH",True
Corticorelin ovine triflutate,Diagnostic,It is used as a diagnostic agent to evaluate the status of the pituitary-adrenal axis in the differentiation of a pituitary source from an ectopic source of excessive ACTH secretion.,SQEPPISLDLTFHLLREVLEMTKADQLAQQAHSNRKLLDIA-NH2,CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CN=CN3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@@H]5CCCN5C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N,A,B,4670.38,41,41,0,no,N.A.,N.A.,no,no,Plasma half-lives for IR-corticorelin are 11.6 ± 1.5 minutes (mean ± SE) for the fast component and 73 ± 8 minutes for the slow component.,No binding,-,IV,US,FDA,1996,Analogue,Human corticotropin-releasing hormone (hCRH),Synthesis - Solid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB09067,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020162s010lbl.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/017697Orig1s012.pdf,https://www.benchchem.com/product/b612370 ,,,,,,,"H, NH2",True
Protirelin,Diagnostic,"Although not currently available in any FDA-approved product, protirelin is a component of the TRH Test where it is used to test the response of the anterior pituitary gland in conditions such as secondary hypothyroidism and acromegaly.",XHP-NH2,[H][C@@](CC1=CN=CN1)(NC(=O)[C@]1([H])CCC(=O)N1)C(=O)N1CCC[C@@]1([H])C(N)=O,B,B,362.39,3,2,0,no,N.A.,N.A.,no,no,"6.5 min (IV), 22 min (nasal), 31 min (oral)",-,-,IV,US,FDA,1976,Natural,Thyrotropin-releasing hormone (TRH),Synthesis,https://go.drugbank.com/drugs/DB09421,https://pubmed.ncbi.nlm.nih.gov/3137012/,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017638,https://drugs.ncats.io/drug/5Y5F15120W,,,,,,"pyroglutamyl, NH2",True
Bacitracin,Therapeutic,Indicated in topical formulations for acute and chronic localized skin infections,XLeIKXIfHdN,CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)[C@@H](C)CC,A,B,1422.71,11,6,4,yes,7,head-to-side chain (amide Lys-Asn),no,no,-,-,"Topical, ophthalmic, and oral formulations of bacitracin are poorly absorbed systemically. Intramuscular bacitracin is readily and completely absorbed","IM, TOPICAL, OPHTALMIC, ORAL",US,FDA,1948,Natural,Bacillus licheniformis strain,Synthesis by nonribosomal peptide synthetases through a thiotemplate mechanism,https://go.drugbank.com/drugs/DB00626,https://www.fda.gov/media/123641/download,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130698/#:~:text=Similar%20to%20other%20polypeptides%20produced,been%20well%20analyzed%20%5B15%5D. ",,,,,,,,"1-amino-2-methylbutyl]-4,5-dihydro-1,3-thiazole-4-carbonyl, cycle",True
Anidulafungin,Therapeutic,"For use in the treatment of the following fungal infections: Candidemia and other forms of Candida infections (intra-abdominal abscess, and peritonitis), Aspergillus infections, and esophageal candidiasis. Also considered an alternative treatment for oropharyngeal canaidiasis.",XXTXXTX,CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC=C(C=C7)O)O)O)[C@@H](C)O)C)O)O)O,A,A,1140.254,7,2,0,yes,6,head-to-side chain,no,no,40-50 hours,84%,100% (IV); 2-7% (ORAL),IV,US,FDA,2006,Analogue,Echinocandin B0 from A. nidulans.,Semisynthesis (fermentation + synthesis),https://go.drugbank.com/drugs/DB00362,https://www.ema.europa.eu/en/documents/scientific-discussion/ecalta-epar-scientific-discussion_en.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021632027_S029lbl.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021632_021948_EraxisTOC.cfm,https://patents.google.com/patent/WO2016056022A2/en ,,,,,,"pentoxyphenyl phenyl benzoyl, cycle",True
Capreomycin,Therapeutic,Used in the treatment of tuberculosis in combination with other drugs.,XAXXXX . XSXXXX,C[C@H]1C(=O)N[C@H](C(=O)N/C(=C/NC(=O)N)/C(=O)N[C@H](C(=O)NC[C@@H](C(=O)N1)N)[C@H]2CCN=C(N2)N)CNC(=O)C[C@H](CCCN)N.C1CN=C(N[C@H]1[C@H]2C(=O)NC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N/C(=C/NC(=O)N)/C(=O)N2)CNC(=O)C[C@H](CCCN)N)CO)N)N,A,A,1321.435,7x2,2,0,yes,5x2,head-to-side chain (Arg-Dap),no,no,4-6 hours,-,Not absorbed in significant quantities from the gastrointestinal tract and must be administered parenterally.,"IM, IV",US,FDA,1971,Natural,Streptomyces capreolus,Fermentation,https://go.drugbank.com/drugs/DB00314,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346614/#:~:text=In%20this%20study%2C%20the%20half,h%20(1)%20in%20humans.",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/050095s072lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050095,,,,,,,"H, cycle",True
Caspofungin,Therapeutic,For the treatment of esophageal candidiasis and invasive aspergillosis in patients who are refractory to or intolerant of other therapies.,XXTXXXX,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@H]([C@H](NC(=O)[C@@H]2[C@H](CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@@H](NC1=O)[C@@H](C)O)O)[C@@H]([C@H](C4=CC=C(C=C4)O)O)O)[C@@H](CCN)O)O)NCCN)O,A,A,1093.331,8,1,0,yes,6,head-to-side chain (3-OH-Hyp-propionic acid),yes,no,9-11 hours,97%,Caspofungin has negligible bioavailability when administered orally; therefore parenteral dosing is indicated. ,IV,US,FDA,2001,Analogue,Pneumocandin B0,Semisynthesis (fermentation + synthesis),https://go.drugbank.com/drugs/DB00520,https://www.cadth.ca/media/pdf/108_No17_caspofungin_edrug_e.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/21227s015lbl.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21227_Cancidas.cfm,https://patents.google.com/patent/US20130231457 ,,,,,,"tridecanoyl, cycle",True
Micafungin,Therapeutic,Treatment of candida,XXTXXXX,CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)[C@@H](CC(=O)N)O)C)O)O)O,A,A,1270.28,7,1,0,yes,6,head-to-side chain (Hyp-Orn),yes,no,14-17 hours,99%,Not absorbed orally,IV,JP,PMDA,2002,Analogue,"Echinocandin-like lipopeptide, isolated from a microbial culture broth.",Semisynthesis (fermentation + synthesis),https://go.drugbank.com/drugs/DB01141,https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021506s009lbl.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021506s023lbl.pdf,https://www.ema.europa.eu/en/documents/assessment-report/mycamine-epar-public-assessment-report_en.pdf,,,,,,,"4-(5-(4-(pentyloxy)phenyl)isoxazol-3-yl-benzoyl, cycle",True
Indium In-111 Pentetreotide,Diagnostic,"Indium In 111 pentetreotide (Octreoscan) has been used in trials studying the diagnostic of SARCOIDOSIS, Solid Tumors, and cushing syndrome.",XfCFwKTCX,CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=N1)[O-])CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N=C(CN(CCN(CCC(C(=O)O)C(=O)O)CC(=O)[O-])CC(=O)[O-])[O-])C(=O)NC(CO)C(C)O)O,A,A,1476.33,9,5,2,yes,6,side chain-to-side chain (disulfide),no,no,The maximum effective half-life of indium In 111 pentetreotide is 10 hours.,-,-,IV,US,FDA,1994,Analogue,Somatostatin ,-,https://go.drugbank.com/drugs/DB11835,https://www.ncbi.nlm.nih.gov/books/NBK501709/,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020314,,,,,,,,"DTPA, 2-aminobutane-1,3-diol",True
Polymyxin B,Therapeutic,"Polymyxin B is indicated for the treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosa",XXTXX(1)XfLXXT(1),[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O,A,B,1203.499,11,3,2,yes,7,head-to-side chain (Thr-Dab),yes,no,9-11.5 hours,92-99%,Administration by the oral route does not lead to absorption,"IM, IV, IT, OPHTALMIC, ORAL, TOPICAL",Canada,CADTH,1951,Natural,Paenibacillus polymyxa,Fermentation and Solid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB00781,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/060716s018lbl.pdf,https://drugs.ncats.io/drug/J2VZ07J96K,https://pubmed.ncbi.nlm.nih.gov/10424344/ ,,,,,,,"6-methyl-octanoyl, cycle",True
Angiotensin II,Therapeutic,Angiotensin II is a vasoconstrictor indicated for increasing blood pressure in adults with septic or other distributive shock,DRVYIHPF,CC[C@@H]([C@@H](C(N[C@H](C(N1CCC[C@H]1C(N[C@H](C(O)=O)CC2=CC=CC=C2)=O)=O)CC3=CN=CN3)=O)NC([C@@H](NC([C@H](C(C)C)NC([C@@H](NC([C@H](CC(O)=O)N)=O)CCCNC(N)=N)=O)=O)CC4=CC=C(C=C4)O)=O)C,A,B,1046.197,8,8,0,no,N.A.,N.A.,no,no,Plasma half-life < 1 min,-,,IV,US,FDA,2017,Natural,-,Synthesis,https://go.drugbank.com/drugs/DB11842,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209360s000lbl.pdf,https://www.fda.gov/news-events/press-announcements/fda-approves-drug-treat-dangerously-low-blood-pressure,,,,,,,,"H, OH",True
Telavancin,Therapeutic,"For the treatment of complicated skin and skin structure infections (cSSSI) caused by gram-positive bacteria like methicillin-susceptible or -resistant Staphylococcus aureus, vancomycin-susceptible Enterococcus faecalis, and Streptococcus pyogenes, Streptococcus agalactiae, or Streptococcus anginosus group. Also for the treatment of adult patients with hospital-acquired bacterial pneumonia (HAP) and ventilator-associated bacterial pneumonia (VAP), known or suspected to be caused by susceptible isolates of Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant S. aureus).",-,CCCCCCCCCCNCCN[C@]1(C[C@@H](O[C@H]([C@H]1O)C)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C(=C(C=C9[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)O)CNCP(=O)(O)O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)C,B,B,1755.65,N.A.,N.A.,N.A.,yes,multicyclic,C-O-C; C-C,yes,yes - 2 sugars, 8 ± 1.5 hours,>90%,Telavancin has poor bioavailability and must be administered over 30-120 minutes IV.,IV,US,FDA,2009,Analogue,Vancomycin,Semisynthesis (fermentation + synthesis),https://go.drugbank.com/drugs/DB06402,https://pubchem.ncbi.nlm.nih.gov/compound/Telavancin#section=ATC-Code,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022407Orig1s000MicroR.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022110s000lbl.pdf,,,,,,,"CH3, OH",True
Telaprevir,Therapeutic,"Telaprevir, when used in combination with Ribavirin, Peginterferon alfa-2a, and Peginterferon alfa-2b is indicated for use in the treatment of chronic HCV genotype 1 infection in adults",-,CCC[C@@H](C(=O)C(=O)NC1CC1)NC(=O)[C@@H]2[C@H]3CCC[C@H]3CN2C(=O)[C@H](C(C)(C)C)NC(=O)[C@H](C4CCCCC4)NC(=O)C5=NC=CN=C5,A,B,679.863,5,0,0,no,N.A.,N.A.,no,no,Telaprevir has a half-life of elimination of 4.0-4.7 hours after a single dose and an effective half life of 9-11 hours at steady state,59-76%,-,ORAL,US,FDA,2011,Heterologous,-,-,https://go.drugbank.com/drugs/DB05521,https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201917lbl.pdf,,,,,,,,,"pyrazinoyl, 3-amino-N-cyclopropyl-2-oxohexanamide",True
Boceprevir,Therapeutic,"Boceprevir, when used in combination with Ribavirin, Peginterferon alfa-2a, and Peginterferon alfa-2b is indicated for use in the treatment of chronic HCV genotype 1 infection in adults",-,CC1([C@@H]2[C@H]1[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)NC(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C,A,B,519.687,4,0,0,no,N.A.,N.A.,no,no,Boceprevir has a mean half-life of elimination of 3.4 hours,75%,-,"SC, ORAL",US,FDA,2011,Heterologous,-,Synthesis,https://go.drugbank.com/drugs/DB08873,https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202258lbl.pdf,,,,,,,,,"CONH-tBu, 3-amino-4-cyclobutyl-2-oxobutanamide",True
Viomycin,Therapeutic,Viomycin is an essential component in the drug cocktail currently used to fight infections of Mycobacterium tuberculosis.,XXSSXX,C1[C@@H](N=C(N[C@H]1O)N)[C@H]2C(=O)NC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N/C(=C\NC(=O)N)/C(=O)N2)CO)CO)NC(=O)C[C@H](CCCN)N,A,A,685.7,7,2,0,yes,5,head-to-side chain (Arg-Dap),no,no,-,-,-,IV,US,FDA,1953,Natural,actinomycete Streptomyces puniceus,Fermentation,https://go.drugbank.com/drugs/DB06827,https://www.sciencedirect.com/topics/neuroscience/viomycin,https://drugs.ncats.io/drug/YVU35998K5,https://pubchem.ncbi.nlm.nih.gov/compound/Viomycin,,,,,,,"H, cycle",True
Demoxytocin,Therapeutic,Analogueue of oxytocin. Labour induction or augmentation,XYIQNCPLG-NH2,CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N,A,A,992.18,9,8,0,yes,6,side chain-to-side chain (disulfide),no,no,-,-,-,BUCCAL,-,-,1971,Analogue,Oxytocin,Synthesis,https://go.drugbank.com/drugs/DB13798,https://www.mims.com/malaysia/drug/info/demoxytocin?mtype=generic,https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:135900,https://drugs.ncats.io/drug/449224,https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:135900,,,,,,"deamino, NH2",True
Pralmorelin,Diagnostic,It is used as a diagnostic agent in a single-dose formulation for the assessment of growth hormone deficiency (GHD),aXAWfK-NH2,C[C@H](C(=O)N[C@H](CC1=CC2=CC=CC=C2C=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@H](CC5=CC=CC=C5)C(=O)N[C@@H](CCCCN)C(=O)N)N,B,B,817.992,6,3,3,no,N.A.,N.A.,no,no,-,-,-,ORAL,JP,PMDA,2004,Analogue,Met-enkephalin,Synthesis,https://drugs.ncats.io/drug/E6S6E1F19M,https://link.springer.com/article/10.2165/00126839-200405040-00011,https://onlinelibrary.wiley.com/doi/full/10.1002/rco2.9,,,,,,,,"H, NH2",True
Enviomycin,Therapeutic,Antibiotic drug acts as an antitubercular agent with less ototoxicity than tuberactinomycin.,XXSSXX,C1CN=C(NC1C2C(=O)NCC(C(=O)NC(C(=O)NC(C(=O)N/C(=C\NC(=O)N)/C(=O)N2)CO)CO)NC(=O)CC(C(CCN)O)N)N,A,A,685.7,7,2,0,yes,5,head-to-side chain (Arg-Dap),no,no,-,-,-,-,JP,PMDA,1975,Natural,Streptomyces griseoverticillatus var. tuberacticus,Fermentation,https://go.drugbank.com/drugs/DB08993,https://books.google.it/books?id=M1p9AgAAQBAJ&pg=PA24&lpg=PA24&dq=enviomycin+approval+year+%221975%22&source=bl&ots=6SSnFSyiNH&sig=ACfU3U1ffYbzh1ISV8vZzq8sp2fjF9eh-w&hl=en&sa=X&ved=2ahUKEwie7NaMjeLuAhWTFMAKHTjxCiQQ6AEwB3oECAkQAg#v=onepage&q=enviomycin%20approval%20year%20%221975%22&f=false,,,,,,,,,"H, cycle",True
Lutetium Lu 177 dotatate,Therapeutic,"Treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.",XFCYWKTCT,C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)N[C@@H]([C@@H](C)O)C(=O)O)O,A,A,1609.55,9,8,0,yes,6,side chain-to-side chain (disulfide),no,no,71 (± 28) hours,The non-radioactive form of lutetium dotatate is 43% bound to human plasma proteins,-,IV,EU - US,EMA - FDA,2016 - 2018,Analogue,Somatostatin,Synthetic,https://go.drugbank.com/drugs/DB13985,https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-dotatate-treatment-gep-nets,https://www.ema.europa.eu/en/documents/assessment-report/lutathera-epar-public-assessment-report_en.pdf,,,,,,,,"DOTA, OH",True
Ombitasvir,Therapeutic,"When used in combination with Paritaprevir and Ritonavir (as the fixed dose product Technivie), Ombitasvir is indicated in combination with Ribavirin for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis. When used in combination with Paritaprevir, Ritonavir, and Dasabuvir (as the fixed dose product Viekira Pak), Ombitasvir is indicated for the treatment of HCV genotype 1b and ,when combined with Ribavirin, for the treatment of HCV genotype 1a.",XVPXPVX,CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)NC2=CC=C(C=C2)[C@@H]3CC[C@H](N3C4=CC=C(C=C4)C(C)(C)C)C5=CC=C(C=C5)NC(=O)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC,A,B,894.127,5,4,0,no,N.A.,N.A.,no,no,21-25 hours,99.9%,48%,ORAL,US,FDA,2014,Heterologous,-,-,https://go.drugbank.com/drugs/DB09296,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206619,,,,,,,,,"MeOAc, 4,4'-(1-(4-(tert-butyl)phenyl)pyrrolidine-2,5-diyl)dianiline",True
Spaglumic acid,Therapeutic,Allergic rhinitis and conjunctivitis,Ac-DE,CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O,A,B,304.255,2,2,0,no,N.A.,N.A.,no,no,-,-,-,EYE DROPS,Portugal and Greece,-,-,Natural,N-Acetylaspartylglutamic acid,-,https://go.drugbank.com/drugs/DB08835,https://drugs.ncats.io/substance/X81L78B3RB,,,,,,,,,"acetyl, OH",True
Perindopril,Therapeutic,"For the treatment of mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease.",XAX,CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O,A,B,368.474,3,1,0,no,N.A.,N.A.,no,no,"Perindopril, 1.2 hours; Peridoprilat, 30-120 hours. The long half life of peridoprilat is due to its slow dissociation from ACE binding sites.",10-20% (perindoprilat),65-75% (perindopril); 20% (perindoprilat),ORAL,EU,EMA,1988,Heterologous,Captopril (derived from viper's venom),-,https://go.drugbank.com/drugs/DB00790,https://www.ema.europa.eu/en/medicines/human/referrals/coversyl-0,,,,,,,,,"ethyl-pentanoyl, OH",True
Ramipril,Therapeutic,"For the management of mild to severe hypertension. May be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction. To reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events. May be used to slow the progression of renal disease in individuals with hypertension, diabetes mellitus and microalubinuria or overt nephropathy.",XAX,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H]3CCC[C@H]3C[C@H]2C(=O)O,A,B,416.518,3,1,0,no,N.A.,N.A.,no,no,"Plasma concentrations of ramiprilat decline in a triphasic manner. Initial rapid decline represents distribution into tissues and has a half life of 2-4 hours. The half life of the apparent elimination phase is 9-18 hours, which is thought to represent clearance of free drug. The half-life of the terminal elimination phase is > 50 hours and thought to represent clearance of drug bound to ACE due to its slow dissociation. The half life of ramiprilat after multiple daily doses (MDDs) is dose-dependent, ranging from 13-17 hours with 5-10 mg MDDs to 27-36 hours for 2.5 mg MDDs.",Protein binding of ramipril is about 73% and that of ramiprilat about 56%.,"The absolute bioavailabilities of ramipril and ramiprilat were 28% and 44%, respectively, when oral administration was compared to intravenous administration.",ORAL,US,FDA,1991,Heterologous,Captopril (derived from viper's venom),-,https://go.drugbank.com/drugs/DB00178,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019901s060lbl.pdf,,,,,,,,,"ethyl-4-phenyl butanoyl, OH",True
Quinapril,Therapeutic,Quinapril is indicated for the treatment of hypertension and as an adjunct therapy in the treatment of heart failure. ,XAX,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)O,A,B,438.524,3,1,0,no,N.A.,N.A.,no,no,The active metabolite quinaprilat has an elimination half life of 2.3 hours,Quinapril and the active metabolite quinaprilat are 97% protein bound in plasma.,Quinapril is 50-80% bioavailable.,ORAL,US,FDA,1991,Heterologous,Captopril (derived from viper's venom),-,https://go.drugbank.com/drugs/DB00881,,,,,,,,,,"ethyl-4-phenyl butanoyl, OH",True
Trandolapril,Therapeutic,"For the treatment of mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure (CHF), to improve survival following myocardial infarction (MI) in individuals who are hemodynamically stable and demonstrate symptoms of left ventricular systolic dysfunction or signs of CHF within a few days following acute MI, and to slow progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy.",XAX,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H]3CCCC[C@@H]3C[C@H]2C(=O)O,A,B,430.545,3,1,0,no,N.A.,N.A.,no,no,"The elimination half lives of trandolapril and trandolaprilat are about 6 and 10 hours, respectively, but, similar to all ACE inhibitors, trandolaprilat also has a prolonged terminal elimination phase that involves a small fraction of administered drug. This likely represents drug binding to plasma and tissue ACE. The effective half life of elimination for trandolaprilat is 16-24 hours.",Serum protein binding of trandolapril is ~ 80% (independent of concentration and not saturable) while that of trandolaprilat is 65 to 94% (concentration-dependent and saturable).,Extensive first pass metabolism results in a low bioavailability of 4-14%,ORAL,US,FDA,1996,Heterologous,Captopril (derived from viper's venom),-,https://go.drugbank.com/drugs/DB00519,https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020528Orig1s000rev.pdf,,,,,,,,,"ethyl-4-phenyl butanoyl, OH",True
Argatroban,Therapeutic,"Argatroban is indicated for prevention and treatment of thrombosis caused by heparin-induced thrombocytopenia (HIT). It is also indicated for use in patients with, or at risk for, HIT who are undergoing percutaneous coronary intervention.",XRX,C[C@@H]1CCN([C@H](C1)C(=O)O)C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C2=CC=CC3=C2NCC(C3)C,B,B,508.64,3,1,0,no,N.A.,N.A.,no,no,39 and 51 minutes,54%,Bioavailability is 100% (intravenous).,IV,US,FDA,2000,Heterologous,-,Synthesis,https://go.drugbank.com/drugs/DB00278,https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022485lbl.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-883_Acova.cfm,,,,,,,,"3-methyl-1,2,3,4-tetrahydroquinoline-8-sulfonic acid, OH",True
Difelikefalin,Therapeutic,Moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis,fflkX,CC(C)C[C@H](C(=O)N[C@H](CCCCN)C(=O)N1CCC(CC1)(C(=O)O)N)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CC3=CC=CC=C3)N,A,A,679.863,5,0,4,no,N.A.,N.A.,no,no,23-31 hours,23-28%,100%,IV,US,FDA,2021,,,Synthesis,https://go.drugbank.com/drugs/DB11938,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214916s000lbl.pdf,,,,,,,,,"H, γ-(4-N-piperidinyl)amino carboxylic acid",True
Setmelanotide,Therapeutic,"Indicated for chronic weight management in patients with obesity due to pro-opiomelanocortin deficiency, proprotein subtilisin/kexin type 1 deficiency, or leptin receptor deficiency",Ac-RCaHfRWC-NH2,C[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC5=CN=CN5,A,,1117.32,8,6,2,yes,7,side chain-to-side chain (disulfide),no,no,Elimination half-life of approximately 11 hours,79.1%,-,SC,US-EU,EMA - FDA,2016 (orphan) - 2020,,,Synthesis,https://go.drugbank.com/drugs/DB11700,https://www.ema.europa.eu/en/documents/assessment-report/imcivree-epar-public-assessment-report_en.pdf,,,,,,,,,"acetyl, NH2",True
Vosoritide,Therapeutic,An analogue of C-type naturietic peptide used to promote bone growth in pediatric patients with achondroplasia.,PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC,CC[C@H](C)[C@H]1C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCNC(=N)N)CC(=O)O)CC(C)C)CCCCN)CC(C)C)CC2=CC=CC=C2)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5=CN=CN5)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@@H]6CCCN6)C(=O)O)CC(C)C)CO)CCSC)CO,A,B,4102.78,39,39,0,yes,17,side chain-to-side chain (disulfide),no,no,21.0-27.9 minutes,-,-,SC,US-EU,EMA - FDA,2021,Analogue,C-type natriuretic pepetide,-,https://go.drugbank.com/drugs/DB11928,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214938s000lbl.pdf,https://www.ema.europa.eu/en/documents/product-information/voxzogo-epar-product-information_en.pdf,https://www.ema.europa.eu/en/documents/assessment-report/voxzogo-epar-public-assessment-report_en.pdf,,,,,,,"H, OH",True
Tirzepatide,Therapeutic,Tirzepatide is a GIP and GLP-1 receptor agonist that controls blood sugar levels in adults with type 2 diabetes.,YXEGTFTSDYSIXLDKIAQKAFVQWLIAGGPSSGAPPPS,CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N4CCC[C@H]4C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N7CCC[C@H]7C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CCCCNC(=O)CCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)C(C)(C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CC=C(C=C8)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC9=CC=CC=C9)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC1=CC=C(C=C1)O)N,B,B,4813.53,39,37,2,no,N.A.,N.A.,yes,no,Approximately 5 days,99% (albumin),The absolute bioavailability of tirzepatide was 80% after subcutaneous administration.,SC,US,FDA,2022,,,Synthetic,https://go.drugbank.com/drugs/DB15171,https://www.fda.gov/news-events/press-announcements/fda-approves-novel-dual-targeted-treatment-type-2-diabetes,https://pubchem.ncbi.nlm.nih.gov/compound/156588324#section=Biologic-Description ,,,,,,,,"H, NH2",True
Rezafungin,Therapeutic,Rezafungin is an echinocandin antifungal that is used for the treatment of candidemia and invasive candidiasis.,XXTXXTX,CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC=C(C=C7)O)O)O)[C@@H](C)O)C)O)OCC[N+](C)(C)C)O,A,B,1225.6,7,2,0,yes,6,"head-to-side chain (g,d- substituted (S)-2,5-diaminopentanoic acid)",yes,no,152 hours.,"Between 87.5% to 93.6% in patients, and between 95.6% to >98.6% in healthy adults.",Bioavailability is 100% (intravenous).,IV,US,FDA,2023,Analogue,Echinocandins class drug,Semisynthesis (fermentation from anidulafungin + synthesis),https://go.drugbank.com/drugs/DB16310,https://pubchem.ncbi.nlm.nih.gov/compound/Rezafungin#:~:text=Rezafungin%20%7C%20C63H85N8O17%2B%20%2D%20PubChem,https://www.fda.gov/media/164723/download,,,,,,,,"4''-(pentyloxy)-[1,1':4',1''-terphenyl]-4-carboxamide, cycle",True
Motixafortide,Therapeutic,Motixafortide is a CXCR4 antagonists and hematopoietic stem cell mobilizer used for treating multiple myeloma.,RRXCYXKKPYRXCR,C1C[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2C1)CCCCN)CCCCN)CCCNC(=O)N)CC3=CC=C(C=C3)O)NC(=O)[C@H](CC4=CC5=CC=CC=C5C=C4)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)C6=CC=C(C=C6)F)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N)CCCNC(=O)N)CCCNC(=N)N)CC7=CC=C(C=C7)O,A,B,2159.6,14,11,0,yes,10,sid,no,no,Approximately 2 hours.,>99%,-,SC,US,FDA,2023,,,Synthetic,https://go.drugbank.com/drugs/DB14939,https://pubchem.ncbi.nlm.nih.gov/compound/Motixafortide ,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217159s000lbl.pdf ,,,,,,,,"Bz(4-F), NH2",True
Flotufolastat F-18,Diagnostic,Flotufolastat F-18 is a radiopharmaceutical diagonistic agent used in PET imaging to visualise prostate cancers with PSMA-positive lesions that suspect metathesis or recurrence.,XeXkXXeXE,CC(C)(C)[Si](C1=CC=C(C=C1)C(=O)NC[C@H](C(=O)N[C@H](CCCCNC(=O)CCC(=O)NCCC[C@H](C(=O)O)NC(=O)CC[C@@H](C(=O)O)NC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)NC(=O)CC[C@@H](C(=O)O)N2CCN(CCN(CCN(CC2)CC(=O)O)CC(=O)O)CC(=O)O)(C(C)(C)C)[18F],A,B,1470.63,9,1,0,no,N.A.,N.A.,no,no,Physical half-life is 109.8 minutes,-,Bioavailability is 100% (intravenous) but 7% is excreted in the urine after 2 hours and 15% execreted at 4.5 hours.,IV,US,FDA,2023,,,Synthetic,https://go.drugbank.com/drugs/DB17851 ,https://pubchem.ncbi.nlm.nih.gov/compound/Flotufolastat-_18F#section=2D-Structure ,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216023s000lbl.pdf ,https://patents.google.com/patent/WO2023047138A1/en?oq=WO2023047138A1 ,,,,,,,"DOTA, OH",True
Pentagastrin,Diagnostic,"Pentagastrin is a gastrin-like molecule used as a diagnostic aid for the evaluation of gastric acid secretory function, gastric hypersecretion, and Zollinger-Ellison tumors.",Boc-bAla-Trp-Met-Asp-Phe-NH2,CC(C)(C)OC(=O)NCCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N,A,,767.9,10,1,0,no,N.A.,N.A.,no,no,10 minutes or less,N.A.,N.A.,IV,US,FDA,2012,Analogue,Gastrin-like peptide,Synthetic,https://go.drugbank.com/drugs/DB00183,https://pubchem.ncbi.nlm.nih.gov/compound/Pentagastrin,,,,,,,,,"Boc, NH2",True
